MX9101237A - Xantinas substituidas y procedimiento para su preparacion - Google Patents

Xantinas substituidas y procedimiento para su preparacion

Info

Publication number
MX9101237A
MX9101237A MX9101237A MX9101237A MX9101237A MX 9101237 A MX9101237 A MX 9101237A MX 9101237 A MX9101237 A MX 9101237A MX 9101237 A MX9101237 A MX 9101237A MX 9101237 A MX9101237 A MX 9101237A
Authority
MX
Mexico
Prior art keywords
preparation procedure
substituted xanthines
xanthines
substituted
procedure
Prior art date
Application number
MX9101237A
Other languages
English (en)
Inventor
Derek Richard Buckle
David Glynn Smith
Ashley Edward Fenwick
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of MX9101237A publication Critical patent/MX9101237A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9101237A 1990-09-26 1991-09-24 Xantinas substituidas y procedimiento para su preparacion MX9101237A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020959A GB9020959D0 (en) 1990-09-26 1990-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
MX9101237A true MX9101237A (es) 1992-05-04

Family

ID=10682788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9101237A MX9101237A (es) 1990-09-26 1991-09-24 Xantinas substituidas y procedimiento para su preparacion

Country Status (12)

Country Link
EP (1) EP0550570A1 (es)
JP (1) JPH06501251A (es)
KR (1) KR930702351A (es)
AU (1) AU653364B2 (es)
CA (1) CA2092430A1 (es)
GB (1) GB9020959D0 (es)
IE (1) IE913350A1 (es)
MX (1) MX9101237A (es)
NZ (1) NZ239921A (es)
PT (1) PT99062A (es)
WO (1) WO1992005175A1 (es)
ZA (1) ZA917610B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930703319A (ko) * 1990-12-21 1993-11-29 데이빗 로버츠 키산틴 유도체
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
CA2206287C (en) * 1994-12-13 2001-03-20 Mark Chasin Aryl thioxanthines
US5821366A (en) * 1995-05-19 1998-10-13 Chiroscience Limited Xanthines and their therapeutic use
DZ2629A1 (fr) * 1997-10-23 2003-03-08 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline procédé pour leur préparation et compositions les contenant.
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
KR20030014394A (ko) * 2000-07-04 2003-02-17 노보 노르디스크 에이/에스 효소 dpp-iv의 억제제인 헤테로고리 화합물
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2302835T3 (es) 2001-08-28 2008-08-01 Schering Corporation Inhibidores de fosfodiesterasa v policiclicos de guanina.
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2284056T3 (es) * 2003-07-31 2007-11-01 Schering Corporation Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.
EP1697363A2 (en) * 2003-12-16 2006-09-06 Ranbaxy Laboratories Limited Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004037554A1 (de) 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039507A1 (de) * 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810295C (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392968B (de) * 1987-01-30 1991-07-25 Sandoz Ag Neue xanthinderivate
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
WO1992007852A1 (en) * 1990-10-25 1992-05-14 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders

Also Published As

Publication number Publication date
EP0550570A1 (en) 1993-07-14
AU653364B2 (en) 1994-09-29
WO1992005175A1 (en) 1992-04-02
GB9020959D0 (en) 1990-11-07
ZA917610B (en) 1992-09-30
PT99062A (pt) 1992-08-31
AU8541391A (en) 1992-04-15
CA2092430A1 (en) 1992-03-27
NZ239921A (en) 1993-12-23
KR930702351A (ko) 1993-09-08
IE913350A1 (en) 1992-04-08
JPH06501251A (ja) 1994-02-10

Similar Documents

Publication Publication Date Title
MX9101237A (es) Xantinas substituidas y procedimiento para su preparacion
MX24568A (es) 3-arilcarbonil-1h-indoles y procedimiento para su preparacion.
MX174176B (es) Compuestos azo y procedimiento para su preparacion
MX9205279A (es) Derivados de benzanilida y procedimiento para su preparacion
MX9205278A (es) Derivados de benzanilida y procedimiento para su preparacion
MX25829A (es) Mezclas de polisacaridos sulfatados y procedimiento para su preparacion.
MX9101793A (es) Derivados de tiazolidindiona y procedimiento para su preparacion
MX26267A (es) Aminobenzodiacepinas y procedimiento para su prepaacion.
MX9101235A (es) Xantinas substituidas y procedimiento para su preparacion
MX9201780A (es) Eteres oximicos y procedimiento para su preparacion.
MX11155A (es) Poliamidas y procedimiento para su obtencion
MX9205316A (es) Sulfonilaminocarboniltriazolinonas y procedimiento para su obtencion
MX9100845A (es) Nuevas tienodiazepinas y procedimiento para su preparacion
MX9100415A (es) Piridinas substituidas y procedimiento para su obtencion
MX9101516A (es) Derivados de 1,2,5,6-tetrahidropiridin 3-cetoxima y-3-aldoxina y procedimiento para su preparacion
MX21243A (es) Indenoindoles y procedimiento para su preparacion.
MX164079B (es) 3-aroiloxifenilcarbamatos polimerizables y metodos para su preparacion y uso
MX9100811A (es) Indolonaftiridinas y procedimiento para su preparacion
MX9205747A (es) Pirazolinas y procedimiento para su preparacion.
MX7829A (es) Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
MX9205746A (es) Pirazolinas y procedimiento para su preparacion.
MX9102583A (es) Microgranallas para vidriado y procedimiento para su obtencion.
MX9100367A (es) Derivados de heteroarilcetona y procedimiento para su preparacion
MX162953B (es) Articulo fotosensible y procedimiento para su preparacion
MX9101794A (es) Compuestos de trifendioxazina y procedimiento para su preparacion

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees